News
1000 Background: Pembrolizumab (pembro) monotherapy showed promising antitumor activity and manageable safety in patients (pts) with metastatic TNBC in KEYNOTE-012, -086 and -119. KEYNOTE-355 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback